08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitNextNext post:AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSRelated PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025Summary of the virtual conference held on October 16, 202516 October 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025
